Gogia A, Sharma A, Raina V, Kumar L, Gupta R, Kumar R. An overview of young chronic lymphocytic leukemia patients: a single centre experience of 117 cases from Northern India. Ann Oncol. 2012;23:ix358.

Article  Google Scholar 

Tejaswi V, Lad DP, Jindal N, et al. Chronic lymphocytic leukemia: real-world data from India. JCO Glob Oncol. 2020;6:866–72. This paper included the largest series of CLL patients from India. This included clinical data of 409 patients and outcomes in the chemoimmunotherapy era.

Article  CAS  PubMed  Google Scholar 

Gunawardana C, Austen B, Powell JE, et al. South Asian chronic lymphocytic leukemia patients have more rapid disease progression than White patients. Br J Hematol. 2008;142(4):606–9.

Article  Google Scholar 

Lad DP, Tejaswi V, Malhotra P, et al. Establishment of a comprehensive chronic lymphocytic leukemia clinic at a tertiary referral center in India. Blood Adv. 2018;2(Suppl 1):33–4.

Article  PubMed  PubMed Central  Google Scholar 

Srinivasan VK, Naseem S, Varma N, Lad DP, Malhotra P. Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression. Blood Res. 2020;55(3):131–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lad DP, Tejaswi V, Jindal N, et al. Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival. Leuk Lymphoma. 2020;61(6):1512–5.

Article  CAS  PubMed  Google Scholar 

Rani L, Gogia A, Singh V, et al. Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in an Indian cohort. Ann Hematol. 2019;98(2):437–43.

Article  CAS  PubMed  Google Scholar 

Gogia A, Gupta R, Sharma A, Kumar L, Rani L, Mallick S. Safety and efficacy of bendamustine and rituximab (BR) regimen in Indian chronic lymphocytic leukaemia patients. Indian J Hematol Blood Trans. 2023;39(1):33–9.

Article  Google Scholar 

Mato A, Nabhan C, Kay NE, et al. Prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization/cytogenetics: a real-world clinical experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018;18(2):114-124.e112.

Article  PubMed  Google Scholar 

Mato A, Nabhan C, Kay NE, et al. Real-world clinical experience in the Connect: chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016;175(5):892–903. This large real-world registry data described the clinical, demographic, and practice patterns for CLL management in the US. This described the infrequent use of genetic prognostic testing and differences in outcomes using chemoimmunotherapy in real-world settings.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Youron P, Singh C, Jindal N, et al. Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire. Eur J Haematol. 2020;105(6):755–62. This study showed that the quality of life of CLL patients on wait-and-watch was severely affected and that patients on ibrutinib had a better QoL than those on chemoimmunotherapy.

Singh C, Jindal N, Youron P, et al. Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients. Indian J Hematol Blood Trans. 2021;37(2):313–7. This is the first study showing the comparable safety and efficacy of generic and innovator ibrutinib.

Article  Google Scholar 

Hegde NC, Kumar A, Kaundal S, et al. Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia. Ann Hematol. 2023;102(11):3125–32. This study showed that generic ibrutinib was cost-effective compared to chemoimmunotherapy at current prices.

Lad DP, Malhotra P, Khadwal A, Prakash G, Jain A, Varma S. Reduced dose ibrutinib due to financial toxicity in CLL. Indian J Hematol Blood Trans. 2019;35(2):260–4.

Article  Google Scholar 

Gogia A, Gupta R, Sharma A, Kumar L, Raina V, Rani L. Chronic lymphocytic leukemia: an Indian experience. J Clin Oncol. 2019;37(15_suppl):e19007–e19007.

Article  Google Scholar 

Jindal N, Lad DP, Malhotra P, et al. Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemoimmunotherapy in CLL. Leuk Lymphoma. 2021;62(7):1674–81.

Article  CAS  PubMed  Google Scholar 

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60. This is the last updated clinical guidelines for the management of CLL by the International Workshop on CLL.

Article  CAS  PubMed  Google Scholar 

Cuneo A, Follows G, Rigolin GM, et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103(7):1209–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sood A, Parihar A, Lad D, Basher R, Singh H, Mittal B. An unusual presentation of Richter's transformation of chronic lymphocytic leukemia in liver and lung on 18 F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography Interesting Image. Indian J Nucl Med. 2020;35(1):70–1.

Lad DP, Varma S, Varma N, et al. Short response duration to initial treatment of autoimmune cytopenias in chronic lymphocytic leukemia. Blood. 2014;124(21):2.

Article  Google Scholar 

Chopra M, Jain A, Chhabra S, et al. Short research communication anti-spike antibody response to COVISHIELD (SII-ChAdOx1 nCoV-19) vaccine in patients with B-cell and plasma cell malignancies and hematopoietic cell transplantation recipients. Indian J Hematol Blood Transfus. 2022;38(4):745–9.

Lad D, Malhotra P, Varma N, et al. CLL: common leukemia; uncommon presentations. Indian J Hematol Blood Transfusion. 2016;32(3):268–75.

Article  Google Scholar 

https://vizhub.healthdata.org/gbd-results?params=gbd-api-2019-permalink/3e3ff112c1fa0a100943150e541687b0 . Accessed July 21.

https://vizhub.healthdata.org/gbd-results?params=gbd-api-2019-permalink/e2915d130d347ac367904a803bd77ebf. Accessed July 21.

Karulkar A, Jain H, Shah S, et al. Making anti-CD19 CAR-T cell therapy accessible and affordable: first-in-human phase I clinical trial experience from India. Blood. 2022;140(Supplement 1):4610–1.

Article  Google Scholar 

Sathyanarayanan V, Flowers CR, Iyer SP. Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between India and the United States. JCO Global Oncol. 2020;6:1124–33.

Article  Google Scholar 

Kater AP, Lanasa MC, Wesselmann J, Fischer K. The 8th young investigators’ meeting on chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(5):1556–9.

Article  Google Scholar